73 MET immunoreactivity and poor prognosis Supplementary table S5: (Continued) Explanatory variable No. of patients 5-year OS 5-year DFS # % HR 95% CI p-value HR 95% CI p-value Vasoinvasive growth Absent 136 75.98 Present 39 21.79 1.785 1.136 – 2.804 0.012 1.557 0.999 – 2.427 0.05 Missing 4 2.23 Bone invasion Absent OR no bone present 140 78.21 Present 39 21.79 1.526 0.965 – 2.412 0.071 1.327 0.845 – 2.085 0.219 Perineural invasion Absent 98 54.75 Present 73 40.78 1.244 0.819 – 1.890 0.306 1.168 0.781 – 1.746 0.450 Missing 8 4.47 Extranodal growth Absent OR pN0 124 69.27 Present 54 30.17 3.927 2.595 – 5.942 < 0.001 3.616 2.423 – 5.396 < 0.001 Missing 1 0.56 Growth pattern Cohesive 36 20.11 Non-cohesive 142 79.33 1.613 0.928 – 2.802 0.090 1.398 0.839 – 2.328 0.198 Missing 1 0.56 Treatment Surgery 50 27.93 Surgery and (C)RT 128 71.51 1.537 0.936 – 2.523 0.089 1.313 0.830 – 2.078 0.245 Missing 1 0.56 Abbreviations: OS, Overall Survival; DFS, Disease Free Survival; HR, Hazard Ratio; CI, Confidence Interval; (C)RT, (chemo)radiotherapy. Bold values highlight statistical significance. 3
RkJQdWJsaXNoZXIy MTk4NDMw